Kyowa Kirin Beheer

Beheer criteriumcontroles 4/4

De CEO Kyowa Kirin is Masashi Miyamoto, benoemd in Mar2018, heeft een ambtstermijn van 6.67 jaar. De totale jaarlijkse vergoeding van { bedraagt ¥ 157.00M, bestaande uit 52.9% salaris en 47.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.019% van de aandelen van het bedrijf, ter waarde $ 1.56M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.3 jaar en 3.2 jaar.

Belangrijke informatie

Masashi Miyamoto

Algemeen directeur

JP¥157.0m

Totale compensatie

Percentage CEO-salaris	52.9%
Dienstverband CEO	6.7yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	3.3yrs
Gemiddelde ambtstermijn bestuur	3.2yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Masashi Miyamoto's beloning veranderd ten opzichte van Kyowa Kirin's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	JP¥84b
Jun 30 2024	n/a	n/a	JP¥97b
Mar 31 2024	n/a	n/a	JP¥83b
Dec 31 2023	JP¥157m	JP¥83m	JP¥81b
Sep 30 2023	n/a	n/a	JP¥58b
Jun 30 2023	n/a	n/a	JP¥40b
Mar 31 2023	n/a	n/a	JP¥50b
Dec 31 2022	JP¥182m	JP¥83m	JP¥54b

Compensatie versus markt: De totale vergoeding ($USD 1.03M ) Masashi } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 7.78M ).

Compensatie versus inkomsten: De vergoeding van Masashi is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Masashi Miyamoto (65 yo)

6.7yrs

Tenure

JP¥157,000,000

Compensatie

Mr. Masashi Miyamoto Ph D., serves as Representative Director at Kyowa Kirin Co., Ltd. He serves as President of Kyowa Hakko Kirin Co., Ltd since March 2018, served as a Chief Operating Officer since March...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Masashi Miyamoto	President	6.7yrs	JP¥157.00m	0.019% $ 1.6m
Motohiko Kawaguchi	CFO & Managing Executive Officer	no data	geen gegevens	geen gegevens
Yutaka Osawa	CCO, Executive VP & Representative Director	2.8yrs	JP¥105.00m	0.013% $ 1.1m
Kazuki Nemoto	Head of Global Legal	1.6yrs	geen gegevens	geen gegevens
Hiroki Nakamura	Global Corporate Communications Head	no data	geen gegevens	geen gegevens
Hiroshi Sonekawa	Managing Executive Officer	3.7yrs	geen gegevens	geen gegevens
Shoko Itagaki	Executive Officer & Chief People Officer	less than a year	geen gegevens	geen gegevens
Takeyoshi Yamashita	Chief Medical Officer	3.8yrs	geen gegevens	0.0054% $ 440.1k
Yasuo Fujii	Chief Strategy Officer	6.8yrs	geen gegevens	geen gegevens
Jean-David Rafizadeh-Kabe	Head of Global Operational Transformation	2.8yrs	geen gegevens	geen gegevens
Yoshifumi Torii	Executive Officer & Head of Global Research	no data	geen gegevens	geen gegevens
Hiroki Takamatsu	VP, Head of Quality Assurance Division & Executive Officer	no data	geen gegevens	geen gegevens

3.3yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KYKO.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Masashi Miyamoto	President	13.6yrs	JP¥157.00m	0.019% $ 1.6m
Yutaka Osawa	CCO, Executive VP & Representative Director	6.7yrs	JP¥105.00m	0.013% $ 1.1m
Takeyoshi Yamashita	Chief Medical Officer	1.7yrs	geen gegevens	0.0054% $ 440.1k
Yoshihisa Q. Suzuki	Independent Outside Director	2.7yrs	geen gegevens	0.00026% $ 21.4k
Hiroshi Komatsu	Full-time Audit & Supervisory Board Member	6.7yrs	geen gegevens	0.00088% $ 72.3k
Akira Morita	Outside Independent Chairman	5.7yrs	geen gegevens	0.00069% $ 56.7k
Yuko Haga	Independent Outside Director	5.7yrs	geen gegevens	0.00088% $ 72.3k
Mayumi Tamura	Outside Audit & Supervisory Board Member	2.7yrs	geen gegevens	0.00012% $ 9.9k
Takashi Oyamada	Independent Outside Director	3.7yrs	geen gegevens	0.00061% $ 50.1k
Shinjiro Akieda	Director	less than a year	geen gegevens	geen gegevens
Rumiko Nakata	Independent Outside Director	1.7yrs	geen gegevens	0.000040% $ 3.3k
Toru Ishikura	Audit & Supervisory Board Member	1.7yrs	geen gegevens	geen gegevens

3.2yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KYKO.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.2 jaar).

Kyowa Kirin Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 25, 2022

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2021

Recent updates

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd. Announces Yutaka Osawa, Executive Vice President and Chief Compliance Officer, Effective March 2025

Kyowa Kirin Co., Ltd. Updates Earnings Guidance for He Fiscal Year 2024

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Kyowa Kirin Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Kyowa Kirin Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2023

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2022, Payable on March 27, 2023; Provides Dividend Guidance for the Second Quarter of 2023

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2022 Results on Feb 07, 2023

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2022

Kyowa Kirin Co., Ltd. Receives European Commission Approval for Use of CRYSVITA(R) (burosumab) for the Treatment of Tumour-Induced Osteomalacia

Kyowa Kirin Co., Ltd. Announces Second Quarter End Dividend for the Fiscal Year Ending December 31, 2022, Payable from September 1, 2022; Provided Year End Dividend Guidance for the Fiscal Year Ending December 31, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending December 31, 2022

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 25, 2022

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Kyowa Kirin Co., Ltd. Announces Publication of New Data Highlighting the Sustained Benefits of Treatment with CRYSVITA® (burosumab) in Adults with X-Linked Hypophosphataemia

Kyowa Kirin Initiates Phase 2 Clinical Study of G-Lasta® for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation in Japan

Kyowa Kirin Co., Ltd. to Present Atopic Dermatitis Clinical Data from Khk4083/Amg 451 Phase 2 Study At the European Academy of Dermatology and Venereology 30Th Congress

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma

Kyowa Kirin Co., Ltd. Announces EU Approval for the Self-administration of CRYSVITA® (burosumab) to Treat X-Linked Hypophosphataemia (XLH)

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. and Kyowa Kirin Announce New Clinical Data on Zandelisib At American Society of Clinical Oncology Annual Meeting 2021

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress

Kyowa Kirin Co., Ltd. Receives Positive CHMP Opinion for the Self-Administration of CRYSVITA® (burosumab) to Treat X-Linked Hypophosphataemia, a Rare Metabolic Bone Disorder

Kyowa Kirin Co., Ltd. to Report Q1, 2021 Results on May 06, 2021

Harvard University and Kyowa Kirin Co., Ltd. Enter into Strategic Research Alliance

Kyowa Kirin Announces Positive Phase 2 Results for KHK4083 in Patients with Moderate to Severe Atopic Dermatitis

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2021

InveniAI LLC and Kyowa Kirin Co., Ltd. Enter AI-Powered Novel Target Discovery Collaboration

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2020 Results on Feb 04, 2021

Kyowa Kirin Announces European Commission (Ec) Approval of CRYSVITA® (Burosumab) for the Treatment of X-Linked Hypophosphataemia (XLH) in Older Adolescents and Adults

Kyowa Kirin Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd